Skip to search boxSkip to navigationSkip to main content

Mitochondrial biogenesis induced by the β2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury

  • Ehtesham Arif
    ,
  • Ashish K. Solanki
    ,
  • Pankaj Srivastava
    ,
  • Bushra Rahman
    ,
  • Wayne R. Fitzgibbon
    ,
  • Peifeng Deng
*Corresponding author for this work
  • Medical University of South Carolina
    ,
  • Department of Veterans Affairs
    ,
  • College of Charleston
    ,
  • ,
  • University of Arizona
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Abstract

Podocytes have limited ability to recover from injury. Here, we demonstrate that increased mitochondrial biogenesis, to meet the metabolic and energy demand of a cell, accelerates podocyte recovery from injury. Analysis of events induced during podocyte injury and recovery showed marked upregulation of peroxisome proliferator-activated receptor-γ coactivator–1α (PGC-1α), a transcriptional co-activator of mitochondrial biogenesis, and key components of the mitochondrial electron transport chain. To evaluate our hypothesis that increasing mitochondrial biogenesis enhanced podocyte recovery from injury, we treated injured podocytes with formoterol, a potent, specific, and long-acting β2-adrenergic receptor agonist that induces mitochondrial biogenesis in vitro and in vivo. Formoterol increased mitochondrial biogenesis and restored mitochondrial morphology and the injury-induced changes to the organization of the actin cytoskeleton in podocytes. Importantly, β2-adrenergic receptors were found to be present on podocyte membranes. Their knockdown attenuated formoterol-induced mitochondrial biogenesis. To determine the potential clinical relevance of these findings, mouse models of acute nephrotoxic serum nephritis and chronic (Adriamycin [doxorubicin]) glomerulopathy were used. Mice were treated with formoterol post-injury when glomerular dysfunction was established. Strikingly, formoterol accelerated the recovery of glomerular function by reducing proteinuria and ameliorating kidney pathology. Furthermore, formoterol treatment reduced cellular apoptosis and increased the expression of the mitochondrial biogenesis marker PGC-1α and multiple electron transport chain proteins. Thus, our results support β2-adrenergic receptors as novel therapeutic targets and formoterol as a therapeutic compound for treating podocytopathies.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 656-673 (18 pages)

Journal (Volume, Issue Number)

Kidney International (Volume 96, Issue 3)

Publication milestones

  • Published - 09/2019

Publication status

Published - 09/2019

ISSN

0085-2538

Publication IDs

  • Scopus: 85067939475
  • PubMed: 31262488
  • ORCID: /0000-0001-9074-4641/work/68515547

Publication metrics

Metrics

SciVal
citations
12
SciVal
FWCI
2.51
SciVal
Author count
15
SciVal
Paper percentile
91
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.07
Fractional count
14
Fractional count
0.93
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
71
Captures
49

Funding Details

This work was supported in whole or in part by NIH grants 2R01DK087956-06A1 and R56 DK116887-01A1 to DN, NIH grant GM084147 to RGS, and the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs BX-000851 to RGS. The authors thank the American Society of Nephrology for the Carl W. Gottschalk Scholar Grant to SHK and the Ben J. Lipps Research Fellowship to AKS. We thank Babita Kumari for technical assistance in the laboratory.
FundersFunding numbers
NIH
2R01DK087956-06A1, GM084147, R56 DK116887-01A1
NIDDK
F31DK105782
VA
BX-000851
ASN
-